Investigation of the iStent Inject® Devices in Open-Angle Glaucoma

Glaucoma, Open-Angle Clinical Trial

Official title:

A Prospective, Unmasked, Single-Site Investigation of the iStent Inject® Devices Implanted in Combination With Cataract Surgery in Patients With Open-Angle Glaucoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03624699
• Other study ID #: GLK-iStent-inject
• Status: Completed
• Phase: N/A
• Start date: April 25, 2018
• Est. completion date: June 30, 2020

Study information

• Verified date: May 2022
• Source: Swiss Vision Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the safety and intraocular pressure (IOP) lowering effect of two iStent inject devices in combination with cataract surgery in patients with mild-to-moderate open-angle glaucoma.

Description:

Patients suffering from open-angle glaucoma who are planning to undergo cataract surgery and are matching the inclusion criteria will be offered to join the study until the desired sample size (50) is reached. Combined cataract-iStent surgery will be performed as per the devices' manufacturers' instructions. Two iStent inject devices will be micro-invasively implanted in the trabecular meshwork of the eye during planned cataract surgery. Six post-operative follow-ups will be carried out over a duration of 12 months, during which various measurements will be made. Performance Outcomes will analyse the proportion of patients with IOP reduction of ≥ 20% vs. baseline mean IOP, at 6 and 12 months. Quality of life outcome will look at the improvement in perceived quality of life as expressed in the NEI VFQ-25 questionnaires from baseline to 3 and 12 months. The rate of adverse events will be recorded.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: June 30, 2020
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma
• Mild to moderate glaucoma (defined as C/D ratio = 0.8)
• Phakic eye requiring cataract surgery
• Preoperative IOP up to 30 mmHg (medicated or not)
• Patients with side-effects to, or complications from, medications
• Patients who would benefit from a reduction of IOP and/or reduction of medication
• Normal angle anatomy as determined by gonioscopy;
• Absence of peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities that could impair proper placement of iStent inject device
• Able and willing to attend scheduled follow-up exams for 12 months postoperatively
• Able and willing to provide written informed consent on the approved Informed Consent Form

Exclusion Criteria:

• Inclusion of the fellow eye in this study (only one eye per subject)
• Aphakic patients or pseudophakic patients
• Prior stent implantations in the study eye
• Eyes with primary angle closure glaucoma, or any secondary angle closure glaucoma
• Traumatic or uveitic glaucoma; or any glaucoma associated with vascular disorders
• Patients with any type of condition that may cause elevated episcleral venous pressure
• Functionally significant visual field loss, including severe nerve fiber bundle defects such as Bjerrum scotoma
• Prior glaucoma treatment (laser or surgery)
• Any active corneal inflammation, edema, or opacity severe-enough to impair gonioscopy / fundus examination
• Any pathology for which, in the investigator's judgment, the following would be either

at risk or contraindicated:

• stent implantation,
• compliance to elements of the study protocol.

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle

Intervention

Device:
• Glaukos iStent inject®
iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma

Locations

Country	Name	City	State
Switzerland	Glaucoma Research Centre, Montchoisi Clinic	Lausanne	VD

Sponsors (2)

Lead Sponsor	Collaborator
Dr. Kaweh Mansouri	Glaukos Corporation

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance Outcome: IOP reduction	Proportion of patients with IOP reduction of = 20% vs. baseline mean IOP, at 12 months.	12 months
Secondary	Quality of life: NEI VFQ-25 score	Improvement in perceived quality of life as expressed in the NEI VFQ-25 (National Eye Institute Vision Function) questionnaires from baseline to 12 months.	12 months
Secondary	Safety Outcome: Adverse events	Rate of adverse events through the follow-up period.	12 months